Kornimate/medical-research-clean huggingface dataset:
our study aims to determine if nerve alterations in acute gbs and cidp detectable by ultrasound match electrodiagnostic findings and if this method aids early diagnosis, predict their outcomes and differentiate between axonal and demyelinating subtypes.

Conditions: Guillain Barré Syndrome; Chronic Inflammatory Demyelinating Polyradiculoneuropathy; Peripheral Nerve Disorder; Peripheral Nerves US; Peripheral Neuropathy

Summary: neuromuscular ultrasound (nmus) is emerging as a valuable non-invasive diagnostic tool. in gbs, nmus can detect proximal nerve enlargement early, before neurophysiological changes. persistent nerve enlargement can be observed up to 15 years, though its correlation with disability varies. research is needed to clarify nmus findings in gbs and cidp over time. early detection of nerve root enlargement via nmus could facilitate earlier diagnosis and intervention, improving patient outcomes and understanding of these conditions\&#39; pathophysiology. this study aims to determine if nerve alterations in acute gbs and cidp detectable by ultrasound match electrodiagnostic findings and if this method aids early diagnosis. the investigators will perform serial nerve ultrasounds and ncs to investigate nerve morphology, predict outcomes, and differentiate between axonal and demyelinating subtypes.


Eligibility criteria:
inclusion criteria: 1. diagnosis of patient group: * gbs patients: diagnosed according to the criteria of the national institute of neurological disorders and stroke (ninds) and the brighton collaboration (2011). * cidp patients: diagnosed according to the criteria of the european federation of neurological societies/peripheral nerve society (efns/pns). 2. age: participants aged 18 to 75 years. 3. onset: * gbs patients: recent onset of gbs within the first 2 weeks of symptom onset. * cidp patients: either relapsing or progressive course consistent with cidp diagnosis. 4. gender: both male and female participants are eligible. 5. participation: willingness to participate in the study, including undergoing disease-related examinations and assessments. 6. consent: ability and willingness to provide informed consent exclusion criteria: 1. patients unable or unwilling to provide informed consent. 2. patients with metabolic disorders or malignancies. 3. patients with other causes of peripheral neuropathy. 4. patients with other causes of acute flaccid paralysis.

Keywords: peripheral nerve ultrasound immune mediated nerve disorders guillain-barré syndrome chronic inflammatory demyelinating polyradiculoneuropathy
early post-marketing study of daclatasvir (daklinza®) + asunaprevir (sunvepra®) in the treatment of chronic hepatitis c (chc) in adults

Conditions: Hepatitis C

Summary: the primary objective of the study is to determine the number of adverse events (aes) reported by chronic hepatitis c (chc) patients receiving at least 1 dose of daclatasvir (dcv) and asunaprevir (asv) at the 2 sentinel sites and that have been reported through the mexican health authority's ae surveillance system during a specified 24-month study period. the secondary objective is to describe aes reported by chc patients receiving treatment with dcv and asv treated by doctors at participating sentinel sites for the national pharmacovigilance center (cnfv) in mexico during a specified 24-month study period.


Eligibility criteria:
for more information regarding bristol-myers squibb (bms) clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * at least 18 years of age with chc, gt-1 * treatment-naïve and treatment-experienced (null or partial) responders * intolerant to interferon (ifn) * with or without cirrhosis exclusion criteria: * patients who received dcv and asv as part of a clinical trial * patients who received dcv and asv for any indication other than that which is locally approved * contraindications included in the approved mexican prescribing information other protocol defined inclusion/exclusion criteria could apply
biomarkers for pharmacoresponse in bipolar disorder - coagulation

Conditions: Bipolar Disorder

Summary: previous studies indicate an association between severe psychiatric disorders, such as bipolar disorder, and increased risk of venous thromboembolism. however, to which extent this association is influenced by lithium treatment is currently unknown. in this prospective cohort study, the investigators aim to investigate the effect of bipolar disorder and lithium treatment on coagulation and the counterpart fibrinolysis.

the investigators will analyse differences in coagulation * using a case-control design where cases are bipolar patients not yet treated with lithium, and controls are healthy volunteers (swedish ethical review authority dnr 2023-05799-02, pi kristoffer månsson, ki). * using a prospective cohort design, following the patients over time.

Eligibility criteria:
inclusion criteria: * patients diagnosed with bipolar disorder but not yet treated with lithium, where there is a decision by the patient and the responsible doctor to start lithium treatment. exclusion criteria: * inability to give informed consent
evaluation of finastride effect in different dosage on the amount of perioperative bleeding in transurthral resection of prostate

Conditions: Benign Prostate Hyperplasia

Summary: preoperative use of finastride will decrease the amount of perioperative blood loss during and after turp the effect of finastride on decreasing the amount of perioperative blood loss during and after turp is dose dependent finastride will decrease microvascular density in prostate tissue and this effect is dose dependent


Eligibility criteria:
inclusion criteria: * patients with bph that require turp exclusion criteria: * previous prostate surgery * prostate cancer * coagulopathy * the use of nsaids, anticoagulants, antiplatelet drugs * crf/esrd
the study of minocycline for negative and cognitive symptoms in schizophrenia

Conditions: Schizophrenia

Summary: the purpose of this study is to determine whether minocycline are effective in the treatment of negative and cognitive symptoms in schizophrenia.

immune-related disorders have been hypothesized as etiological factors in schizophrenia.minocycline is a second-generation tetracycline that exerts anti-inflammatory and antimicrobial effects while having a distinct neuroprotective profile.this study was performed as a double-blind, placebocontrolled,randomized evaluation of second generation antipsychotics(sga) and minocycline versus sga and placebo.

Eligibility criteria:
inclusion criteria: * male and female,were aged 18-40 years * were currently diagnosed with dsm-iv schizophrenia * were able to comprehend the cognition test * patients or guardian signed informed consent,were able to comprehend the procedure and aims of the study,agreed to join the study * patient's current antipsychotic medication regimen must be stable * must be in a stable living arrangement exclusion criteria: * had ever been hypersensitivity to minocycline or tetracycline; * had acute,unstable,significant,or untreated medical illness besides schizophrenia * were pregnant or breast-feeding; * had a dsm-iv diagnosis of substance abuse or dependency; * had a tendency to suicide or violence,self-harm; * had taken immunosuppressive agents in the preceding 3 months before study entry; * had influenza or fever in the preceding 2 weeks before study entry; * had a dsm-iv diagnosis of emotional psychosis,mental retardation,etc. * has suicidal attempts or ideation or violent behavior within the last 12 months * patient has mental retardation or severe organic brain syndromes * treatment with electroconvulsive therapy (ect) within 6 months prior to screening

Keywords: schizophrenia minocycline cognition
the differences in the psychological states of patients with different chronic hip pain

Conditions: Psychological Disorders; Hip Pain Chronic

Summary: nowadays, studies related to the psychological state of patients with chronic hip pain are still limited, and there is a lack of research on the characteristics of the psychological state of patients with chronic soreness from different pain sources. the goal of this retrospective cross-sectional study was to reveal differences between the psychological states of chronic hip pain patients with different pain sources. the main question it aims to answer is whether there are differences in psychological states among hip pain patients with intra-hip pain, extra-hip pain, and intra-hip combined with extra-hip pain.


Eligibility criteria:
inclusion criteria: * the subject must be at least 16 years old and of sound mind； * chronic hip pain persisting for a duration exceeding 3 months. exclusion criteria: * previous mental illness and cognitive impairment； * other serious illnesses such as heart failure, respiratory failure, malignant tumours, severe trauma and other serious illnesses;； * chronic pain lasting for more than 3 months in other parts of the body;； * use of prescribed opioid drugs exceeding 60 mg morphine equivalent per day or steroid analgesics.

Keywords: hip pain psychological disorders depression anxiety
ms-detect: early detection of multiple sclerosis progression with mscopilot® detect

Conditions: Multiple Sclerosis

Summary: the study aims to evaluate mscopilot® detect, a smartphone application for at-home monitoring of patients with multiple sclerosis (ms). the primary objective is to enhance and standardize remote monitoring of ms patients to accurately assess disease progression caused by either relapse activity worsening (raw) or progression independent of relapses (pira). the study also aims to assess the safety, usability, and satisfaction of the solution. a secondary objective is to determine mscopilot® detect's ability to provide early detection of disease changes and predict changes in expanded disability status scale (edss) scores in more patients. exploratory objectives include evaluating the relationship between mscopilot® detect composite and individual scores and other biomarkers such as mri, soluble glial fibrillary acidic protein (sgfap), and soluble neurofilament light chain (snfl). patients will be able to download the free mscopilot® detect app. they will participate in 1 inclusion visit and 3 follow-up visits, scheduled at 6 months, 12 months, and 18 months (an additional visit at 24 months may be scheduled if necessary). every 3 months, patients will complete validated questionnaires regarding ms symptoms and quality of life and participate in digital tests designed to monitor ms symptom progression. the study will include 336 ms patients and will be conducted in the united states, canada, germany, italy, spain, denmark and france


Eligibility criteria:
inclusion criteria: * adult patients living with rrms or spms, aged 30 to 65 * edss score between 2.5 to 6.5 points * with a disease duration \> 5 years * clinically stable during the last 3 months before inclusion (no relapses, no disability progression) * no change in the dmt\* during the last 3 months before inclusion * receiving optimal symptomatic treatments at baseline (clinician's judgment) * owns a personal smartphone which mobile operating system is above 14 for ios (iphone) and 8 for android included with a good internet connexion * able to use a smartphone * able to read language in wich the mobile application is available and able to understand pictograms. * applicable to patients enrolled in france only: affiliated to a social security system. exclusion criteria: * medically unstable conditions that may hinder patient's ability to comply with the study procedures * inability to use a smartphone or mscopilot® detect application * patient with corrected visual acuity less than 4/10 (monoyer) or 20/50 (snellen at 20 feet) or +0,4 (logmar) * pregnancy and nursing women * persons under guardianship or curatorship * current drugs or/and alcohol abuse that could influence performance on the tests (clinician's judgment) * patients have participated in another clinical study within the previous 30 days of screening or are currently participating in another study that, in the opinion of the investigator, might interfere with the patient's full participation in the study or confound the assessment of the patient or outcome of the study.
safety and efficacy of igiv 10% in patients with autoimmune encephalitis:

Conditions: Autoimmune Encephalitis

Summary: the purpose of this study is to evaluate the safety and efficacy of igiv 10% in patients with autoimmune encephalitis


Eligibility criteria:
inclusion criteria: 1. male or female, aged more than 12 years.(adolescent or adult) 2. subject who all three of the following diagnosis criteria for possible autoimmune encephalitis have been met. * subacute onset (rapid progression of less than 3 months) of working memory deficits(short-term memory loss), altered mental status, or psychiatric symptoms. * at least one of the following: * new focal cns findings * seizure not explained by a previously known seizure disorder * csf pleocytosis (wbc count ≥ 5/mm2) * mri features suggestive of encephalitis * reasonable exclusion of alternative causes 3. subjects or parent/legal representative willing to provide written informed consent exclusion criteria: 1. subject who has received immunoglobulin therapy within 10 weeks prior to screening 2. subject who has a history of hypersensitivity or shock to ingredient of immunoglobulin 3. subject who has been diagnosed with iga deficiency 4. subject who has renal disorder (creatinine clearance \< 10 ml/min) or requires dialysis 5. subject who has been diagnosed with hemolytic anemia or anemia from blood loss 6. subject who has been diagnosed with immuonological competence or immunodeficiency 7. subject who has high risk of thrombus or embolism (history of thrombus/embolism or cerebro/cardiovascular disorder within 3 months prior to screening) 8. subject who has low heart condition (congestive heart failure \>nyha functional class ⅱ: unstable coronary artery disease or myocardiac infarction within 3 months prior to screening) 9. subject who cannot prohibit the previously administrated steroids by investigator's discretion (ex. suspicion of steroid dependence, hypoadrenocorticism, when treatment effects are expected, etc.) 10. females who are pregnant or breast feeding 11. subject who is considered by investigator to ineligible for the study.
a phase ii study of pegylated interferon alfa-2b for the adjuvant treatment of melanoma subjects in russia (mk-4031-400)

Conditions: Melanoma

Summary: this study will assess the safety of pegylated interferon alfa-2b (peg-ifn) as an adjuvant treatment for melanoma.


Eligibility criteria:
inclusion criteria: * competent to self-administer the subcutaneous injections of peg-ifn * histologically documented involved regional lymph nodes of a primary cutaneous melanoma or unknown primary, meeting the study's staging criteria * had the primary melanoma completely resected with adequate surgical margins and undergone operation for positive regional lymph nodes within 84 days of study start * eastern cooperative oncology group performance status (ecog ps) score of 0 or 1 * adequate hepatic, renal and bone marrow function as defined by study parameters obtained within 4 weeks prior to study start * for a female subject who is of childbearing potential or male participant with female sexual partner who is of childbearing potential, agree to use acceptable methods of contraception for at least 2 weeks prior to study start and continue until at least 6 months after last dose of study medication, or longer if dictated by local regulations exclusion criteria: * mucous membrane melanoma or ocular melanoma * known hypersensitivity to the components of study drug (including acetaminophen), or its analogs * evidence of distant or non-regional lymph node metastases or in-transit metastases * disease that cannot be completely surgically resected * prior malignancy within the past 5 years other than surgically cured non-melanoma skin cancer or cervical carcinoma in situ * severe cardiovascular disease, i.e. arrhythmias, requiring chronic treatment, congestive heart failure or symptomatic ischemic heart disease * hepatic decompensation * thyroid dysfunction not responsive to therapy * uncontrolled diabetes mellitus * clinically active autoimmune disease * clinically active and/or uncontrolled infection, including active hepatitis * human immunodeficiency virus (hiv) * history of neuropsychiatric disorder requiring hospitalization * actively abusing alcohol or drugs * pregnant, lactating, or of reproductive potential and not using an effective means of contraception * medical condition requiring chronic systemic corticosteroids * received any experimental therapy within 30 days prior to enrolling in this study * received any prior chemotherapy, immunotherapy, hormonal or radiation therapy for melanoma * previously received interferon-α for any reason * known serious hypersensitivity reaction to peg-ifn or interferon alfa-2b
pulpotomy in carious permanent mature teeth: pulp survival and risk factors

Conditions: Pulpitis; Pulp Exposure, Dental; Pulp and Periapical Tissue Disease

Summary: this trial evaluated the extent of pulp survival following pulpotomy in the permanent tooth pulp exposed by caries and identify potential risk factors for pulpal complications.

healthy patients ≥ 21 years old were recruited with informed consent. inclusion criteria were symptomatic and asymptomatic periodontally sound teeth, positive response to pulp sensibility tests, pulp exposure by caries with bleeding, haemostasis achieved within 10 minutes and normal apical tissues. under local anaesthesia and rubber dam isolation, caries was removed before pulpotomy. pain complaint, clinical and radiographic data were collected during recalls for up to 3 years.

Eligibility criteria:
inclusion criteria: patient factors: * male and female at least 21 years of age * healthy and ambulant * mild diseases only and without substantive functional limitations * able to return for scheduled recalls tooth factors: * deep caries leading to pulp exposure * with or without pre-operative spontaneous and/or aggravated pain * positive response to cold and electric pulp tests * positive bleeding on pulp exposure * haemostasis within 10 minutes * intact and continuous periodontal ligament space and dental lamina dura on radiograph exclusion criteria: patient factors: * younger than 21 years of age * pregnant female * poorly controlled systemic diseases e.g. diabetes mellitus, hypertension tooth factors: * extensive tooth structure loss requiring post and core retained restoration * uncontrolled periodontal disease * cracked tooth * traumatized tooth * haemostasis not achieved within 10 minutes

Keywords: pulpotomy permanent teeth deep caries management risk factors clinical indicators for pulpotomy
surveillance study of viral infections following lung transplantation

Conditions: Lung Transplantation; Bronchiolitis Obliterans; Epstein-Barr Virus Infections; Paramyxoviridae Infections

Summary: the present study was conducted to study the impact community acquired respiratory virus (carv) infections in an outpatient setting on graft function of lung transplant recipients. the study was aimed to identify risk factors for carv infections. the study was further intended to investigate an association of epstein-barr virus (ebv), cytomegalovirus (cmv) and human adenovirus (hadv) with the development of bos and to identify risk factors for virus detection in blood.

informed consent was obtained from the ltx recipients and the study was approved of by the institutional review board of hannover medical school. ltx recipients are screened for carv infections during the cold season (end october until end april) in a single-centre outpatient clinic. symptoms of upper (urti) and lower respiratory tract infections (urti) are recorded by questionnaires and findings. nasopharyngeal and oropharyngeal swabs (nos) were performed to detect rv-antigens by immunofluorescence testing (ift) of respiratory-syncytial virus (rsv), adenovirus, parainfluenza (piv), influenza and cultures for carv are performed. bal was performed when clinically indicated and processed by ift. multiplex-pcr to detect 14 carv are processed in symptomatic patients. in addition blood samples are monitored at each contact to investigate an association of epstein-barr virus (ebv), cytomegalovirus (cmv) and human adenovirus (hadv) with the development of bos and to identify risk factors for virus detection in blood.

Eligibility criteria:
inclusion criteria: * adults 18-70 years * lung transplantation (including single, double, combination and re-do transplants) exclusion criteria: * refused consent

Keywords: lung transplantation bronchiolitis obliterans epstein-barr virus infections paramyxoviridae infections herpesviridae
prevalence of ocular surface disease in glaucoma patients

Conditions: Glaucoma

Summary: demographic information and a brief medical and concomitant medicine history will be obtained from the glaucoma patient's records. qualified patients will be asked to complete a questionnaire about their symptoms. patients will then be scheduled to undergo three standard clinical tests of the ocular surface.


Eligibility criteria:
inclusion criteria: * diagnosis of glaucoma; * other protocol-defined inclusion criteria may apply. exclusion criteria: * inability to understand trial procedures; * inability to understand informed consent; * current use or use within the last 3 months of restasis, steroids, or topical ocular non-steroidal anti-inflammatory drugs; * punctal plugs; * previous glaucoma, corneal, or conjunctival surgery; * other protocol-defined exclusion criteria may apply.

Keywords: glaucoma ocular hypertension dry eye ocular surface disease
safety and efficacy of ingap-peptide in patients with type 2 diabetes

Conditions: Diabetes Mellitus, Non-Insulin-Dependent

Summary: insulin is a chemical that the body needs in order to use or store sugar. it is made by a type of cell called a beta cell which resides in an organ known as the pancreas. type 2 diabetes is a disease where the beta cells are unable to meet a person's insulin needs. sugar levels rise in the blood as a result. ingap-peptide is being tested to attempt to create new beta cells in the pancreas, and to improve the ability to produce insulin in type 2 diabetic patients.


Eligibility criteria:
inclusion criteria * age 35-70 * using \>20 units of insulin per day * hba1c from 6.5% to 10% * no islet antibodies * otherwise healthy

Keywords: type 2 diabetes
deep venous thrombosis in non-severe covid-19 patients hospitalized for a neurovascular pathology

Conditions: Deep Venous Thrombosis

Summary: severe sars-cov-2 infection, responsible of covid-19, is accompanied by many venous thromboembolic events. antithrombotic treatment is the cornerstone of management of many neurovascular diseases (nvds) and the benefit-risk ratio is crucial to avoid hemorrhagic complications. therefore, in non-severe covid-19 patients affected by nvds, the diagnostic of deep venous thrombosis (dvt) is challenging. using bedside doppler ultrasonography (dus) of lower limbs, this study investigated the rates of dvt in these patients in stroke unit.


Eligibility criteria:
* inclusion criteria: * age\>18 years * covid-19 confirmed with rt-pcer and/or chest ct-scan * acute neurovascular disease defined as transient ischemic attack or acute ischemic stroke or venous cerebral thrombosis or hemorrhagic stroke. * exclusion criteria: * age\<18 * other neurovascular diseases

Keywords: non-severe covid-19 neurovascular diseases doppler ultrasound deep venous thrombosis covid-19 sars-cov-2